Hepatitis C Virus and Antiviral Drug Resistance = Hepatitis C Virus and Antiviral Drug Resistance

다국어 초록 (Multilingual Abstract)

Since its discovery in 1989, hepatitis C virus (HCV) has been intensively investigated to understand its biology and develop effective antiviral therapies. The efforts of the previous 25 years have resulted in a better understanding of the virus, and this was facilitated by the development of in vitro cell culture systems for HCV replication. Antiviral treatments and sustained virological responses have also improved from the early interferon monotherapy to the current all-oral regimens using direct-acting antivirals. However, antiviral resistance has become a critical issue in the treatment of chronic hepatitis C, similar to other chronic viral infections, and retreatment options following treatment failure have become important questions. Despite the clinical challenges in the management of chronic hepatitis C, substantial progress has been made in understanding HCV, which may facilitate the investigation of other closely related flaviviruses and lead to the development of antiviral agents against these human pathogens. (Gut Liver 2016;10:890-895)

참고문헌 (Reference)

1 Feinstone SM, "Transfusion-associated hepatitis not due to viral hepatitis type A or B" 292 : 767-770, 1975

2 Miyanari Y, "The lipid droplet is an important organelle for hepatitis C virus production" 9 : 1089-1097, 2007

3 Ding Q, "The impact of hepatitis C virus entry on viral tropism" 16 : 562-568, 2014

4 Jacobson IM, "Telaprevir for previously untreated chronic hepatitis C virus infection" 364 : 2405-2416, 2011

5 Tellinghuisen TL, "Structure of the zincbinding domain of an essential component of the hepatitis C virus replicase" 435 : 374-379, 2005

6 Yu M, "Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture" 58 : 2638-2646, 2014

7 Lohmann V, "Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line" 285 : 110-113, 1999

8 Saeed M, "Replication of hepatitis C virus genotype 3a in cultured cells" 144 (144): 56-58, 2013

9 Kim S, "Regulation of the production of infectious genotype 1a hepatitis C virus by NS5A domain III" 85 : 6645-6656, 2011

10 Yamane D, "Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation" 20 : 927-935, 2014

11 Tellinghuisen TL, "Regulation of hepatitis C virion production via phosphorylation of the NS5A protein" 4 : e1000032-, 2008

12 Shimakami T, "Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus" 140 : 667-675, 2011

13 Wakita T, "Production of infectious hepatitis C virus in tissue culture from a cloned viral genome" 11 : 791-796, 2005

14 Yi M, "Production of infectious genotype 1a hepatitis C virus (Hutchinson strain)in cultured human hepatoma cells" 103 : 2310-2315, 2006

15 Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial" 358 : 958-965, 2001

16 Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection" 347 : 975-982, 2002

17 McGivern DR, "Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors" 147 (147): 453-462, 2014

18 Choo QL, "Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome" 244 : 359-362, 1989

19 Lin R, "Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates: results of the first multicentre Australian trial. Australia Hepatitis C Study Group" 23 : 487-496, 1995

20 McHutchison JG, "Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group" 339 : 1485-1492, 1998

21 Masaki T, "Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles" 82 : 7964-7976, 2008

22 Bartosch B, "Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes" 197 : 633-642, 2003

23 Li YP, "Highly efficient full-length hepatitis C virus genotype 1(strain TN) infectious culture system" 109 : 19757-19762, 2012

24 Huang H, "Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins" 104 : 5848-5853, 2007

25 Wose Kinge CN, "Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents" 58 : 5386-5394, 2014

26 Lontok E, "Hepatitis C virus drug resistance-associated substitutions: state of the art summary" 62 : 1623-1632, 2015

27 Paul D, "Hepatitis C virus RNA replication and assembly: living on the fat of the land" 16 : 569-579, 2014

28 Lemon SM, "Fields virology. Volume 1" Lippincott Williams and Wilkins 1253-1304, 2007

29 Appel N, "Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly" 4 : e1000035-, 2008

30 Saeed M, "Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells" 56 : 5365-5373, 2012

31 Blight KJ, "Efficient initiation of HCV RNA replication in cell culture" 290 : 1972-1974, 2000

32 Peng B, "Development of robust hepatitis C virus genotype 4 subgenomic replicons" 144 : 59-61, 2013

33 Kim S, "Development of hepatitis C virus genotype 3a cell culture system" 60 : 1838-1850, 2014

34 Alter HJ, "Clinical and serological analysis of transfusionassociated hepatitis" 2 : 838-841, 1975

35 Gao M, "Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect" 465 : 96-100, 2010

36 Karino Y, "Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir" 58 : 646-654, 2013

37 Gastaminza P, "Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion" 82 : 2120-2129, 2008

38 Poordad F, "Boceprevir for untreated chronic HCV genotype 1 infection" 364 : 1195-1206, 2011

39 Yi M, "Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells" 78 : 7904-7915, 2004

40 Poynard T, "A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis: Multicenter Study Group" 332 : 1457-1462, 1995

41 Heim MH, "25 Years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end" 13 : 535-542, 2013